stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Current ratio
Kymera Therapeutics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 11.1×, up 0.7× from fiscal 2025 (10.5×). Over the past ten years it has ranged from 2.7× (fiscal 2019) to 10.5× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 10.5× | 39.05% |
| FY2024 | 7.5× | 59.19% |
| FY2023 | 4.7× | (19.54%) |
| FY2022 | 5.9× | 20.56% |
| FY2021 | 4.9× | 78.41% |
| FY2020 | 2.7× | 1.77% |
| FY2019 | 2.7× | (69.88%) |
| FY2018 | 8.9× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 11.1× | 7.67% |
| Jun 2026 | 10.3× | (4.42%) |
| Mar 2026 | 10.8× | 3.29% |
| Dec 2025 | 10.5× | 41.85% |
| 22 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. | 11.1× |
| SMMT Summit Therapeutics PLC compare | 7.0× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| PCVX Vaxcyte, Inc. compare | 5.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TECH Bio-Techne Corp compare | 4.5× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| BMRN BioMarin Pharmaceutical Inc. compare | 2.4× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement